As a rheumatologist, you’re used to having goals. After all, you set your sights on becoming a physician, achieved the necessary educational degrees and passed required exams. After meeting your educational goals, you landed a job at an academic medical center or an established rheumatology practice, or you may have started your own practice. So…
PARIS (Reuters)—One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in western France of an experimental medicine from an unnamed drug company, the French health ministry said on Friday, Jan. 15. The ministry did not say what the medicine was intended to be used…
Rheumatologists practicing in rural and urban areas face different challenges. Robert Jackson, DO, discusses how technology, healthcare reform and hospital closures affect rheumatology practice in rural areas and its future…
(Reuters Health)—U.S. emergency rooms are increasingly running short on medications, including many that are needed for life-threatening conditions, a recent study documents. Since 2008, the number of shortages has risen by more than 400%, researchers found. Half of all emergency room shortages were for life-saving drugs, and for one in 10 there were no available…
(Reuters)—Anthem Inc. could save $3 billion annually on drug costs from a re-pricing provision in its current contract with pharmacy benefits manager Express Scripts Holding Co, the health insurer’s chief executive officer said Tuesday. Anthem said it is working to renegotiate the contract this year to avoid overpaying for pharmaceuticals based on current market conditions….
(Reuters)—Three large U.S. venture capital firms are betting that hospitals will buy into a new service designed to help healthcare providers treat their patients more like upscale hotels treat their customers. The new company, called Docent Health, is creating software and mobile applications that will help organize and monitor every aspect of an individual’s hospital…
Sarilumab is proving effective for treating RA. In a clinical trial, pregabalin did not meet its endpoint for treating post-traumatic peripheral neuropathic pain. And a 12-hour ibuprofen patch is in development…
(Reuters)—The chief executive of HCA Holdings Inc. on Monday said he expects the Affordable Care Act to drive more growth for the U.S. hospital operator in 2016 as Americans sign up for insurance coverage through exchanges created under the law. “We are very encouraged by the open enrollment results so far,” R. Milton Johnson, CEO…
(Reuters)—Healthcare investors can expect a volatile week starting on Monday when the sector’s biggest financial event hits San Francisco. The annual JP Morgan healthcare conference, in which many healthcare companies present product and financial news to would-be investors, has been credited for helping the January out-performance of the healthcare sector in recent years. But after…
In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…